why choose us

First received: October 17, 2023

Clinical Trial: Phase II Clinical Trial of Interleukin-2 in AD

Study Status: Completed

Recruit Status: RECRUITING

Condition: Alzheimer Disease

Study Type: INTERVENTIONAL


Official Title: A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients With Mild to Moderate Alzheimer's Disease

Brief Summary: Neuroinflammation is a significant component of Alzheimer disease (AD).Our group recently demonstrated that regulatory T cells (Tregs) have a compromised phenotype and reduced suppressive function in AD patients, skewing the immune system toward a proinflammatory status and potentially contributing to disease progression.Low dose interleukin-2 (IL-2) is now viewed as a promising immunoregulatory drug with the capacity to selectively expand and restore functional Tregs.This study is a phase II, randomized,…

Read more